Related Experiment Video
Updated: Jun 6, 2026

The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse
Published on: July 25, 2011
Protective role for type 4 metabotropic glutamate receptors against ischemic brain damage
Slavianka G Moyanova1, Federica Mastroiacovo, Lidia V Kortenska
1Department of Neurobiology of Processes of Adaptation, Institute of Neurobiology, Bulgarian Academy of Sciences, Sofia, Bulgaria.
Abstract:
We examined the influence of type 4 metabotropic glutamate (mGlu4) receptors on ischemic brain damage using the permanent middle cerebral artery occlusion (MCAO) model in mice and the endothelin-1 (Et-1) model of transient focal ischemia in rats. Mice lacking mGlu4 receptors showed a 25% to 30% increase in infarct volume after MCAO as compared with wild-type littermates. In normal mice, systemic injection of the selective mGlu4 receptor enhancer, N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-caboxamide (PHCCC; 10 mg/kg, subcutaneous, administered once 30 minutes before MCAO), reduced the extent of ischemic brain damage by 35% to 45%. The drug was inactive in mGlu4 receptor knockout mice. In the Et-1 model, PHCCC administered only once 20 minutes after ischemia reduced the infarct volume to a larger extent in the caudate/putamen than in the cerebral cortex. Ischemic rats treated with PHCCC showed a faster recovery of neuronal function, as shown by electrocorticographic recording and by a battery of specific tests, which assess sensorimotor deficits. These data indicate that activation of mGlu4 receptors limit the development of brain damage after permanent or transient focal ischemia. These findings are promising because selective mGlu4 receptor enhancers are under clinical development for the treatment of Parkinson's disease and other central nervous system disorders.
Insights
Activation of metabotropic glutamate 4 (mGlu4) receptors protects against ischemic brain damage. Enhancing mGlu4 receptors reduced infarct volume and improved functional recovery in rodent models of stroke.
Area of Science:
- Neuroscience
- Pharmacology
- Ischemic Stroke Research
Background:
- Ischemic brain damage significantly contributes to neurological deficits.
- Metabotropic glutamate 4 (mGlu4) receptors are implicated in neuronal function and survival.
- Understanding the role of mGlu4 receptors in ischemia is crucial for developing neuroprotective strategies.
Purpose of the Study:
- To investigate the neuroprotective effects of mGlu4 receptor activation in models of focal cerebral ischemia.
- To evaluate the impact of mGlu4 receptor deficiency on ischemic brain injury.
- To assess the therapeutic potential of selective mGlu4 receptor enhancers in stroke.
Main Methods:
- Permanent middle cerebral artery occlusion (MCAO) model in mGlu4 receptor knockout and wild-type mice.
- Endothelin-1 (Et-1) induced transient focal ischemia model in rats.
- Administration of a selective mGlu4 receptor enhancer (PHCCC) before or after ischemic insult.
- Assessment of infarct volume, neuronal function (electrocorticography), and sensorimotor deficits.
Main Results:
- Mice lacking mGlu4 receptors exhibited a 25-30% increase in infarct volume after MCAO.
- Systemic administration of PHCCC reduced ischemic brain damage by 35-45% in normal mice, but was ineffective in knockout mice.
- PHCCC treatment post-ischemia reduced infarct volume in the caudate/putamen and cerebral cortex in the Et-1 model.
- PHCCC-treated rats demonstrated faster recovery of neuronal function and improved sensorimotor performance.
Conclusions:
- Activation of mGlu4 receptors confers significant neuroprotection against both permanent and transient focal cerebral ischemia.
- Selective mGlu4 receptor enhancers, like PHCCC, show therapeutic promise for treating ischemic stroke.
- These findings support the clinical development of mGlu4 receptor modulators for central nervous system disorders, including stroke and Parkinson's disease.
Related Concept Videos
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Antiepileptic Drugs: Glutamate Antagonists
The Blood-brain Barrier
Ischemic Stroke ll: Pathophysiology

